Legal & General Group Plc decreased its holdings in Bruker Co. (NASDAQ:BRKR - Free Report) by 7.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 191,919 shares of the medical research company's stock after selling 14,652 shares during the period. Legal & General Group Plc owned about 0.13% of Bruker worth $11,250,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in BRKR. Bank of Montreal Can lifted its position in Bruker by 6.4% in the 4th quarter. Bank of Montreal Can now owns 65,029 shares of the medical research company's stock worth $3,812,000 after buying an additional 3,891 shares in the last quarter. Polymer Capital Management US LLC acquired a new position in shares of Bruker in the fourth quarter worth $249,000. Cerity Partners LLC raised its holdings in shares of Bruker by 2.8% during the fourth quarter. Cerity Partners LLC now owns 28,782 shares of the medical research company's stock worth $1,730,000 after acquiring an additional 784 shares in the last quarter. Quadrant Capital Group LLC boosted its position in Bruker by 18.2% during the fourth quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company's stock valued at $75,000 after purchasing an additional 196 shares during the last quarter. Finally, Envestnet Asset Management Inc. grew its stake in Bruker by 10.8% in the fourth quarter. Envestnet Asset Management Inc. now owns 354,106 shares of the medical research company's stock valued at $20,758,000 after purchasing an additional 34,464 shares in the last quarter. 79.52% of the stock is owned by hedge funds and other institutional investors.
Bruker Stock Performance
Shares of NASDAQ:BRKR traded up $0.98 during midday trading on Tuesday, hitting $36.96. The company's stock had a trading volume of 2,289,628 shares, compared to its average volume of 1,506,328. Bruker Co. has a fifty-two week low of $34.10 and a fifty-two week high of $83.32. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60. The stock has a market capitalization of $5.60 billion, a price-to-earnings ratio of 48.63, a PEG ratio of 2.16 and a beta of 1.18. The stock's 50 day simple moving average is $43.92 and its 200 day simple moving average is $53.25.
Bruker (NASDAQ:BRKR - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, topping the consensus estimate of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. As a group, research analysts anticipate that Bruker Co. will post 2.69 earnings per share for the current year.
Bruker Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Monday, March 17th were issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.54%. The ex-dividend date was Monday, March 17th. Bruker's dividend payout ratio (DPR) is presently 26.32%.
Wall Street Analyst Weigh In
A number of equities research analysts have recently weighed in on the company. Wells Fargo & Company cut their price target on Bruker from $75.00 to $60.00 and set an "overweight" rating for the company in a research note on Thursday, April 17th. Stifel Nicolaus cut their price objective on shares of Bruker from $70.00 to $57.00 and set a "hold" rating on the stock in a research report on Friday, February 14th. Citigroup decreased their target price on shares of Bruker from $75.00 to $50.00 and set a "buy" rating for the company in a research report on Monday, April 7th. Guggenheim restated a "buy" rating on shares of Bruker in a report on Monday, February 24th. Finally, Barclays reduced their price objective on shares of Bruker from $60.00 to $50.00 and set an "overweight" rating for the company in a research note on Thursday, April 10th. Six research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $65.00.
View Our Latest Research Report on BRKR
About Bruker
(
Free Report)
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Featured Stories
Before you consider Bruker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.
While Bruker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
